JACC:脉冲消融治疗房颤安全有效

2019-07-26 不详 MedSci原创

使用射频或冷冻疗法等热能进行的心房颤动导管消融会造成组织的破坏。在脉冲消融(PFA)过程中,亚电场在细胞膜上产生微小的孔,这一过程称为电穿孔。在各种细胞类型中,心肌细胞具有最低阈值,可能允许优先心肌的消融。本研究的目的旨在评估PFA是否可以达到持久的肺静脉(PV)隔离而不损害侧支结构。本次两项临床试验探究了基于导管的PFA对发作性房颤的有效性和安全性。在所有的81名患者中,所有患者的肺静脉均被单相

使用射频或冷冻疗法等热能进行的心房颤动导管消融会造成组织的破坏。在脉冲消融(PFA)过程中,亚电场在细胞膜上产生微小的孔,这一过程称为电穿孔。在各种细胞类型中,心肌细胞具有最低阈值,可能允许优先心肌的消融。本研究的目的旨在评估PFA是否可以达到持久的肺静脉(PV)隔离而不损害侧支结构。

本次两项临床试验探究了基于导管的PFA对发作性房颤的有效性和安全性。在所有的81名患者中,所有患者的肺静脉均被单相(n=15)或双相(n=66)的PFA急性分离出来,手术的操作平均时间为 92.2±27.4min,透视的平均时间为13.1±7.6min。通过连续的波形改进,所有的肺静脉隔离患者3个月的耐久性从18%提高到100%。除了一例操作相关的心包填塞外,术后120天内无其他主要不良事件发生。

研究结果显示,脉冲消融优先影响心肌组织,可以达到快速的肺静脉隔离和良好的耐受性和安全性。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854463, encodeId=d253185446310, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jan 25 10:42:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009814, encodeId=b2b02009814e8, content=<a href='/topic/show?id=d73e844655f' target=_blank style='color:#2F92EE;'>#脉冲消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84465, encryptionId=d73e844655f, topicName=脉冲消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Sep 03 17:42:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326288, encodeId=1fbd132628802, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421783, encodeId=b8e61421e83e8, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597748, encodeId=05d1159e74862, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=)]
    2020-01-25 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854463, encodeId=d253185446310, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jan 25 10:42:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009814, encodeId=b2b02009814e8, content=<a href='/topic/show?id=d73e844655f' target=_blank style='color:#2F92EE;'>#脉冲消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84465, encryptionId=d73e844655f, topicName=脉冲消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Sep 03 17:42:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326288, encodeId=1fbd132628802, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421783, encodeId=b8e61421e83e8, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597748, encodeId=05d1159e74862, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854463, encodeId=d253185446310, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jan 25 10:42:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009814, encodeId=b2b02009814e8, content=<a href='/topic/show?id=d73e844655f' target=_blank style='color:#2F92EE;'>#脉冲消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84465, encryptionId=d73e844655f, topicName=脉冲消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Sep 03 17:42:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326288, encodeId=1fbd132628802, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421783, encodeId=b8e61421e83e8, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597748, encodeId=05d1159e74862, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854463, encodeId=d253185446310, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jan 25 10:42:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009814, encodeId=b2b02009814e8, content=<a href='/topic/show?id=d73e844655f' target=_blank style='color:#2F92EE;'>#脉冲消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84465, encryptionId=d73e844655f, topicName=脉冲消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Sep 03 17:42:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326288, encodeId=1fbd132628802, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421783, encodeId=b8e61421e83e8, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597748, encodeId=05d1159e74862, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854463, encodeId=d253185446310, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jan 25 10:42:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009814, encodeId=b2b02009814e8, content=<a href='/topic/show?id=d73e844655f' target=_blank style='color:#2F92EE;'>#脉冲消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84465, encryptionId=d73e844655f, topicName=脉冲消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Sep 03 17:42:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326288, encodeId=1fbd132628802, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421783, encodeId=b8e61421e83e8, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597748, encodeId=05d1159e74862, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Sun Jul 28 00:42:00 CST 2019, time=2019-07-28, status=1, ipAttribution=)]

相关资讯

JAHA:人口密度增加,可能带来心脏获益

随全球城市化程度不断加深,许多城市的人口密度迅速增加。人口密度增加对心血管健康会产生什么影响?带着这个疑问,研究人员对城市人口密度增加(城市人口致密化)对澳大利亚成人心血管危险因素的潜在影响展开调查,并将结果发表于近期出版的《美国心脏协会杂志》(Journal of the American Heart Association)。

JAMA子刊:警惕“苹果型”身材!即使BMI正常,也与全因死亡率、心血管和癌症死亡率风险增加相关

“苹果型”身材 - 即使体重指数(BMI)在正常范围内,也与腰围高的肥胖患者的全因死亡率、心血管和癌症死亡率风险增加相似。

JACC:单一高敏肌钙蛋白检测可进行心梗危险分层

本研究的目的旨在通过单次测量的高敏肌钙蛋白I(hs-cTnI)进行急性心梗的危险分层。本次前瞻性多中心观察研究纳入了来自29个美国医疗中心的疑似急性心梗患者,并用两种检测方法对其hs-cTnI水平进行了检测。最终共纳入了2212名患者,有12%患者发生心梗,检测或定量的限制导致急性心肌梗死或30天死亡的极高敏感性(范围98.6%至99.6%)和阴性预测值(范围99.5%至99.8%)。hs-cTn

盘点:JACC七月第三期研究一览

1.伊多沙班和华法林对房颤伴肝脏疾病史患者的影响研究

NEJM连发两文:中国有能力做好全球创新药临床研究!

肾性贫血新希望,Roxadustat强势登场!收缩压与舒张压可独立预测心血管结局!

JACC:急性暴发性心肌炎和非暴发性心肌炎的预后研究

急性暴发性心肌炎(FM)是一类以严重左室收缩功能不全为特征的心肌炎,预后差。一项单中心研究显示FM患者的预后较伴左室收缩功能不全的急性非暴发性心肌炎(NFM)患者更好。本研究的目的旨在进一步明确FM的预后。本研究纳入了220名(平均年龄42岁,女性占46.3%)病理证实为心肌炎且左室收缩功能不全的患者,其中165名为FM患者。主要终点事件是入院后60内的心源性死亡和预期随访后的心脏移植。与NFM患